drugset
Drugs / 13-valent Pnumococcal Conjugate vaccine
last change Nov 2019 re-read 3 minutes ago

13-valent Pnumococcal Conjugate vaccine

also known as 13-valent pneumococcal conjugate vaccine · PCV13

Vaccine

Developed for
pneumococcal infection
Investigated by
Pfizer

Trials 1

today NCT01692886 · Ph 3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01692886 Sep 2012 → Apr 2014 pneumococcal infection Pfizer Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 13-valent Pnumococcal Conjugate vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01692886 ↗
Known as 13-valent pneumococcal conjugate vaccine “BACKGROUND: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China based on immunologic noninferiority to 7-valent PCV (PCV7).” PMID 31626050 ↗ Nov 2019
Known as PCV13 “BACKGROUND: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China based on immunologic noninferiority to 7-valent PCV (PCV7).” PMID 31626050 ↗ Nov 2019
Modality Vaccine “13-valent pneumococcal conjugate vaccine” NCT01692886 ↗